ARWR: Receives EU Approval
Arrowhead Pharmaceuticals receives European Commission marketing authorization for REDEMPLO to lower triglyceride levels in adult patients with familial chylomicronemia syndrome
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ARWR Receives EU Approval
Arrowhead Pharmaceuticals receives EU marketing authorization for REDEMPLO to reduce triglycerides in adults with Familial Chylomicronemia Syndrome